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Abstract: sFas (CD95) / FasL are hallmarks of apoptosis involvement in pathogenesis of HIV. We assess changes in soluble 
Fas /FasL, CD4 % and HIV-1 viral load in patients prior to the initiation of antiretroviral therapy (ART) and 6 months 
thereafter. A prospective longitudinal study on sixty consented HIV-1 positive adults. sFas and sFasL levels were measured by 
ELISA. CD4 cell counts and HIV-1 viralloads were measured using standard methods. Samples were analysed according to the 
manufacturers’ guidelines.There was a significant positive correlation between HIV-1 viral load and FasL at six months (M6) 
on treatment [r = +0.49, (0.03)]. There were no correlation between sFas/FasL and CD4 cell counts [ r = -33 (0.16), -31 (0.17) -
23 (0.03) respectively]. The significant correlation between sFasL and HIV-1 viral load at six months of ART suggests that 
sFasL could be a signal biomarker for HIV-1 disease progression. We have shown in this study that high levels of sFasL depict 
high HIV-1 viral loads and advance state of the HIV disease. These biomarker should be investigated further in other settings. 
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1. Introduction 
Monitoring treatment success of patients on ART is solely 
dependent on HIV viral load assays [1]. The CD4 absolute 
cell count and CD4 cell % are routinely used in Cameroon 
and many other Sub-Saharan African countries as a baseline 
prior to treatment. They are also used for monitoring 
treatment outcomes due to limited HIV viral load testing 
facilities available. Immunological and virological responses 
are required for better evaluation of patient success, 
especially after 6 months of ART initiation. 
Fas-Ligand (FasL, CD95L) is a homotrimetric membrane-
molecule. It is a type II membrane protein belonging to the 
Tumour Necrosis Factor (TNF) and the Nerve Growth 
Superfamilies, (NGS). Their C-terminal regions are outside 
the cell, with a three cystein-rich domain (CRD) [3-4]. FasL 
are expressed only while the T-lymphocytes are activated. 
The expression of FasL is induced in T-cells through 
activation via their T-cell receptor (Fas, Apo-1, CD95) (4-6). 
The extracellular region of Fas has significant homology to 
the corresponding region of other members of the TNF 
family. Each FasL trimer binds three Fas receptor molecules 
on the surface of the targeted cells [4-5]. The Fas receptor 
(target cell) is the antagonist of FasLigand (effector cells). 
When they are cross-linked during the immune activation of 
T-Cells, it leads to an up-regulation of apoptosis of CD4. The 
Activated Induced Cell Death (AICD) pathways of apoptosis 
is involved in this up-regulation, leading to an uncontrolled 
depletion of CD4 T-cells, as witnessed in immune depressed 
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HIV patients [10-11]. 
Recent studies have highlighted the biological interaction 
of many viral and host factors, such as host genetics, immune 
response and their involvement in the pathogenesis of HIV 
disease. Members of the TNFR super family could mediate 
pleiotropic biological processes, such as cell proliferation, 
differentiation, apoptosis and cytokine production [4-9]. 
Several other studies had shown a significant increase of Fas 
receptors and ligand levels in plasma or serum of HIV-1 
infected individuals, compared to their negative control 
subjects [10-17]. These studies also demonstrated the 
involvement of the Fas/FasL pathways in predicting HIV-1 
disease progression. In our previous studies in resource 
limited settings in Cameroon we demonstrated that Fasligand 
(CD95L) were better alternatives, compared to the commonly 
used CD4 absolute or CD% for baseline and in monitoring 
disease progression in infants and adults on ART (23). 
HIV-1 viral load testing is the gold standard test 
recommended for monitoring patients’ success with ART [18-
22]. However, their availability, due to high cost, as 
demonstrated in our previous study in Cameroon [24] requires 
the need to identify alternative approaches for monitoring ART 
in resource-limited settings. The study objective was to assess 
the changes in sFasL, CD4 cell counts, CD4 % and HIV-1 
viral load prior to and after the initiation of ART. 
2. Materials and Method 
2.1. Study Design 
This was a prospective longitudinal study conducted 
between September 2012 and February 2013. Sixty HIV 
positive patients were recruited from the Center for the Study 
and control of Communicable Diseases (CSCCD), Faculty of 
Medicine and Biomedical Sciences, University of Yaoundé, 
Cameroon. Patients were screened for CD4 cell count and HIV 
viral load and were referred from different health units around 
the city of Yaoundé, Cameroon. All participants were those 
earmarked for ART with their baseline CD4 cell counts below 
350 copies/ml. Initiation of ART was taken at time (M0) and 
all patients were followed-up after 6 months of treatment 
(M6). Demographic information was collected for each 
participant using a standard questionnaire and consent form. 
Ten milliliters of whole blood were collected under standard 
conditions in EDTA anticoagulant tubes and 50µl was used for 
CD4 absolute cell count and percentages. Plasma was obtained 
after centrifugation of whole blood at 12000 rpm for 5 
minutes. The plasma was separated in less than four hours after 
blood collection in EDTA anticoagulant tubes. 
2.2. Ethical Considerations 
Ethical clearance was obtained from the Cameroon 
National Ethics Committee (Reg 049/CNE/SE/2012). 
Participation in this study was voluntary. A signed consent 
form was obtained from all participants. All procedures were 
standard and only involved minimal risk to the participants. 
Study results were returned to the patients and incorporated 
into their medical records. The results were readily available 
to their medical practitioners. 
2.3. Measurement of sFas Levels 
Soluble Fas levels were assayed using a quantitative 
sandwich Enzyme-linked Immune-Sorbent Assay kit for both 
the receptors and the ligands (Quantikine®, R&D Systems, 
UK), strictly using the manufacturer’s instructions. The 
wavelength and optical density were measured at 450 nm 
using an ELISA reader (Sunrise Tecan Austria GMBH 5082 
Microplate Reader) and all samples were assayed in 
duplicate. The concentration of sFas in plasma samples were 
determined extrapolating the results from a standard curve. 
2.4. HIV-1 Viral Load and CD4+ Cell Counts 
We used the commercial kits manual (Amplicor 1.5, Roche 
diagnostics, Germany) an RT-PCR assay. This was 
performed with a prepared Master Mix containing 
oligonucleotide primers Specific to regions of the HIV-1 gag 
genes with upstream sense primers of (sk145) 
5′(AGTGGGGGGACATCAAGCAGCCATGCAAAT3′) and 
the downer stream antisense, (skcc1B) SKCC1B (5′-
TACTAGTAGTTCCTGCTATGTCACTTCC-3′). The 
detection and quantification was done using coated 
hybridization probes. The optical density and wave lengths 
were measured and extrapolated curves generated to 
calculate results. The minimum detection limit of the kits was 
2.3log10. CD4+ counts were done using the Automated 
FAScount machine from Becton Dickinson (Abbott France) 
both the CD4 and Viral loads were done simultaneously to 
generate both baseline values. Samples were analysed based 
on the manufacturers’ guidelines. 
2.5. Statistical Analysis 
Data were analysed using STATA version 11 (STATA, 
Corps Texas, USA). Six month changes in Fas ligand levels 
were compared to six month HIV viral load changes using 
the Pearson correlation coefficient. Changes of HIV viral 
load were considered significant with a log difference of 0.5 
between two viral load scores. The Mann Whitney test was 
used to compare association. 
3. Results 
3.1. Patient Demographics 
Of the sixty participants enrolled in the study, 38 (63.3%; 
n=60) were female and 22 (36.6%; n=60) male. Their ages 
range from 20 to 61, with a mean of 34.3 (SD=7.8). The 
information is summarized in Table 1. All participants 
receive first line ART according to the WHO and Cameroon 
national guidelines. 
3.2. Baseline Data (Mo) 
3.2.1. HIV Viral Load and sFasLigands Levels 
The HIV viral load levels ranged from 3.7 to 5.4 log10 
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with a mean value of 4.8, while the Fasligand concentration 
ranged from 51 to 321 pg/ml with a mean value of 153.7 
(Table 2). 
Table 1. Demographic data of study Population. 
Gender N = (60) % 
Male 38/60 63.3 
Female 22/60 36.6 
Age Group(Years)   
20-25 2/60 3.3 
26-31 6/60 10 
32-37 33/60 55 
<38 19/60 31 
Marital Statue   
Married 23/60 38 
Single 37/60 61 
Table 2. Baseline and Six months Data. 
Base line values Log10/copies/ml/pg/ml Means 
HIV-1 viral load 3.7 - 5.4 4.8  
FasLigand (CD95L/127) 
concentrations 
51 - 321 153.7 
Six months on ART   
HIV viral loads 1.3 - 3.4. 3.1 
FasLigand (CD95L/127) 
concentrations 
27 - 231 88.1. 
3.2.2. sFasR, CD4 Cell Counts 
sFas, CD4 levels ranged from 95 to 300 pg/ml, 200 
to500m3 and 30 - 40%, respectively. At six months HIV 
viral loads, sFas, sFasL and CD4 levels were 1.3 to 3.4 
log10, 80 to 290 pg/ml, 27 to 231 pg/ml, 200 to 650 mm and 
30 to 45%. 
3.3. Data at (M6) 
3.3.1. HIV-Viral Load and FasL(M6) 
At six months on ART the HIV viral load and Fasligand 
levels showed a significant fall with their ranged of 1.3 to 3.4 
log10 with a mean of 3.1, while the Fasligand concentration 
ranged from 27 to 231 pg/ml,with a mean of 88.1 (Table 2). 
3.3.2. sFasR, CD4 Absolute and CD4% (M6) 
At six months sFas, CD4 levels ranged from 1.3 to 3.4 
log10, 80 to 290 pg/ml, 200 to 650mm
3
 and 30 to 45%. These 
changes were not statistacally signiicant. 
3.4. Substantial Change After Six-Month in HIV Viral 
Load and Fasligands Levels 
The values show substantial change at after six-month with 
ranged from -3.5 to +0.3 log10 with a mean of -1.7, while the 
FasL concentration ranged from -260 to +81pg/ml. Twenty 
patients had <1log change in HIV-1 viral load and a mean 
decrease of FasL levels of -5.4 pg/ml, while the forty patients 
had >1log decrease in HIV-1 viral load and a mean decrease 
in Fas ligand concentration of - 87.2 pg/ml with a (p-value = 
0.06) (Table 2). 
 
Figure 1. The scatterd plot  illustrates the correlation between six-month 
changes in HIV-1 viral and SFasligand Levels. The X-axis shows the 
difference in HIV Viral load while the Y- axis shows the sFasligand 
concentration. (r=+0.49, p-value= 0.03). 
3.5. Substantial Change After Six-Month in HIV Viral 
Load and sFasligands Levels 
The values show substantial change at after six-month with 
ranged from -3.5 to +0.3 log10 with a mean of -1.7, while the 
FasL concentration ranged from -260 to +81pg/ml. Twenty 
patients had <1log change in HIV-1 viral load and a mean 
decrease of FasL levels of-5.4 p g/ml, while the forty patients 
had >1log decrease in HIV-1 viral load and a mean decrease in 
Fas ligand concentration of - 87.2 pg/ml with a p-value=0.06. 
 
Figure 2. Box plot illustrates the substantial change in HIV-1 viral load and 
Fasigand using a < and >1 Log. The middle horizontal lines represent the 
median concentrations of sFas ligands and HIV-1 viral loads >1log and 
<1log. 
4. Discussion 
Fas and FasL play critical roles in the immune system, 
including the killing of pathogens in infected cells, causing 
death of absolute and potentially dangerous lymphocytes. They 
have also been shown to play critical roles in HIV-1 
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pathogenesis [1-4]. This study aimed at assessing the six-
month (M6) change in both FasL levels in comparison with 
HIV-1 viral load. Limited studies have been performed to 
evaluate the correlation between the apoptotic immunologic 
marker FasL (CD95L) and the gold standard virologic marker 
(HIV-1 viral load) used in monitoring patients on ART [5-9]. 
We have previously done a cost analysis to show the potential 
of using Fas and FasL as a cheaper alternative to evaluate ART 
outcomes (Ikomey et al., 2012; Ikomey et al., 2013). 
The mean age of the study population was 34.4 (SD ± 7.8), 
with 63.3% of patients being male and 36.6% female. Our 
results show that the majority of patients at baseline, before 
ART, had HIV-1 viral loads above 3.5 log10 and FasL levels 
above 300 ng/dl. Other studies have also shown high FasL 
levels of above 3log for treatment naïve patients [6]. The 
elevated levels of both biomarkers at baseline could be as a 
result of the high viral burden and immune activation of T-
cells observed in naïve to early treated HIV-1 positive 
patients. These high levels of FasL could potentially indicate 
an increase in HIV-1 viral load and an advanced state of 
disease progression.  
After six months on ART the HIV-1 viral load and FasL 
levels were significantly reduced, from 1.3 to 3.4 log10 and 27 
to 231 pg/ml, respectively. The significant decrease in both the 
FasL and HIV-1 viral load levels could be interpreted as the 
result of the reduced viral burden due to ART. ART reduces the 
pressure of immune activation exerted on the cells, thereby 
reducing the apoptotic action of the Fas/FasL. 
We have previously shown study results that demonstrated 
a positive correlation between HIV-1 viral loads and Fas 
ligand levels in HIV positive adults and children. This is the 
first longitudinal study we have done to evaluate FasL and 
HIV-1 viral loads over time [10-14]. We have shown the 
potential use of FasL in monitoring HIV disease progression 
in children, especially in resource limited settings.  
We hypothesize that high levels of FasL in HIV-1 positive 
patients depict a high and clear signal of CD4 T-cell 
depletion. The results show that a high level of T-cell 
depletion could indicate a high HIV viral load and visa-versa. 
The strength of this study is the fact that it was performed 
in Yaoundé, Cameroon, a resource limited setting in which 
alternative and cheaper methods are required to monitor HIV 
positive patients. The limitation of this study was the non 
inclusion of children and patients failing ART treatments. 
This will be done in a follow-up study. 
5. Conclusion 
The significant correlation between sFasL and HIV-1 viral 
load at six months of ART suggests that sFasL could be a 
better and more affordable alternative biomarker of HIV 
disease progression compared to CD4 absolute and CD%, 
currently being used in resource limited settings. We have 
shown in this study that high levels of sFasL depict high 
HIV-1 viral loads. And advance state of the disease. These 
biomarker should be investigated further in other settings. 
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